ADC Target Novelty Intelligence for Pharma BD

ADC Target Novelty Intelligence: SaaS ingesting a biotech's ADC pipeline (antibody, linker, payload, target) and outputting a structural novelty score vs. clinical-stage ADCs, patents, and deal comparables—sold to pharma BD

Oncology 38% of global pipeline (cross-verified). Gilead/Tubulis $5B ADC deal (cross-verified). Biotech investors pay $50-200K per deal for expert ADC scientific review. Pharma BD at $300K+ per enterprise contract.

G020 categorical vs incremental: ADC novelty scoring is categorical—does not exist as standalone product. But incumbent (Biotech Trial Due Diligence from prior sessions) could absorb as vertical extension. G006 feature gravity well: Clarivate/Cortellis and expert networks (GLG, Third Bridge) could absorb.

Pivot: sell to pharma BD (Gilead, Daiichi, Roche) rather than investors. Different buyer, larger deal size ($300K+), longer sales cycle (6-12 months). BD angle is better—larger budgets and stronger ADC-specific pain.

Survived Pass 1 at 38% conviction after BD pivot. Primary worry: Clarivate or Evaluate Pharma launches ADC module within one release cycle.

SciPath.ai discovered: ADC target intelligence startup, seed funded May 2025. Focus is target selection for pharma R&D, not investor due diligence specifically, but narrows the 'no competitor' claim significantly.

FEATURE gate BORDERLINE FAIL: Clarivate owns the pharma BD desktop, has the patent/trial/deal database, could launch ADC novelty module in one release cycle. Pharma BD would stay with Clarivate. Standalone player needs 12-18 month lead AND proprietary data asset (exclusive expert network, ADC litigation dataset) to defend—neither exists.

KILLED IN DEEPENING at 32% conviction (below 35% floor). Clarivate absorption risk genuine, SciPath.ai seed narrows window, 9-12 month sales cycle means first revenue Q1 2027 minimum—mismatched to ADC deal urgency signal.